Literature DB >> 28333488

The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies.

Roman Kotov1, Robert F Krueger2, David Watson3, Thomas M Achenbach4, Robert R Althoff4, R Michael Bagby5, Timothy A Brown6, William T Carpenter7, Avshalom Caspi8, Lee Anna Clark3, Nicholas R Eaton9, Miriam K Forbes2, Kelsie T Forbush10, David Goldberg11, Deborah Hasin12, Steven E Hyman13, Masha Y Ivanova4, Donald R Lynam14, Kristian Markon15, Joshua D Miller16, Terrie E Moffitt8, Leslie C Morey17, Stephanie N Mullins-Sweatt18, Johan Ormel19, Christopher J Patrick20, Darrel A Regier21, Leslie Rescorla22, Camilo J Ruggero23, Douglas B Samuel14, Martin Sellbom24, Leonard J Simms25, Andrew E Skodol26, Tim Slade27, Susan C South14, Jennifer L Tackett28, Irwin D Waldman29, Monika A Waszczuk30, Thomas A Widiger31, Aidan G C Wright32, Mark Zimmerman33.   

Abstract

The reliability and validity of traditional taxonomies are limited by arbitrary boundaries between psychopathology and normality, often unclear boundaries between disorders, frequent disorder co-occurrence, heterogeneity within disorders, and diagnostic instability. These taxonomies went beyond evidence available on the structure of psychopathology and were shaped by a variety of other considerations, which may explain the aforementioned shortcomings. The Hierarchical Taxonomy Of Psychopathology (HiTOP) model has emerged as a research effort to address these problems. It constructs psychopathological syndromes and their components/subtypes based on the observed covariation of symptoms, grouping related symptoms together and thus reducing heterogeneity. It also combines co-occurring syndromes into spectra, thereby mapping out comorbidity. Moreover, it characterizes these phenomena dimensionally, which addresses boundary problems and diagnostic instability. Here, we review the development of the HiTOP and the relevant evidence. The new classification already covers most forms of psychopathology. Dimensional measures have been developed to assess many of the identified components, syndromes, and spectra. Several domains of this model are ready for clinical and research applications. The HiTOP promises to improve research and clinical practice by addressing the aforementioned shortcomings of traditional nosologies. It also provides an effective way to summarize and convey information on risk factors, etiology, pathophysiology, phenomenology, illness course, and treatment response. This can greatly improve the utility of the diagnosis of mental disorders. The new classification remains a work in progress. However, it is developing rapidly and is poised to advance mental health research and care significantly as the relevant science matures. (PsycINFO Database Record (c) 2017 APA, all rights reserved).

Entities:  

Mesh:

Year:  2017        PMID: 28333488     DOI: 10.1037/abn0000258

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  370 in total

1.  Making the Most of It: Application of Planned Missingness Design to Increase the Efficiency of Diagnostic Assessment.

Authors:  Zvi R Shapiro; Cynthia Huang-Pollock; John W Graham; Kristina Neely
Journal:  J Psychopathol Behav Assess       Date:  2020-01-08

2.  RDoC and Psychopathology among Youth: Misplaced Assumptions and an Agenda for Future Research.

Authors:  Theodore P Beauchaine; Stephen P Hinshaw
Journal:  J Clin Child Adolesc Psychol       Date:  2020 May-Jun

3.  Positive and Negative Activation in the Mood Disorder Questionnaire: Associations With Psychopathology and Emotion Dysregulation in a Clinical Sample.

Authors:  Ryan W Carpenter; Kasey Stanton; Noah N Emery; Mark Zimmerman
Journal:  Assessment       Date:  2019-05-29

4.  Toward a Complex Network of Risks for Psychosis: Combining Trauma, Cognitive Biases, Depression, and Psychotic-like Experiences on a Large Sample of Young Adults.

Authors:  Łukasz Gawęda; Renata Pionke; Jessica Hartmann; Barnaby Nelson; Andrzej Cechnicki; Dorota Frydecka
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

5.  Addiction Models and the Challenge of Having Impact.

Authors:  Meyer D Glantz
Journal:  Alcohol Clin Exp Res       Date:  2019-07-16       Impact factor: 3.455

Review 6.  Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences.

Authors:  Christian Grillon; Oliver J Robinson; Brian Cornwell; Monique Ernst
Journal:  Neuropsychopharmacology       Date:  2019-06-21       Impact factor: 7.853

7.  Test-retest & familial concordance of MDD symptoms.

Authors:  Ariela J E Kaiser; Carter J Funkhouser; Vijay A Mittal; Sebastian Walther; Stewart A Shankman
Journal:  Psychiatry Res       Date:  2020-07-20       Impact factor: 3.222

8.  Exploring Comorbidity Within Mental Disorders Among a Danish National Population.

Authors:  Oleguer Plana-Ripoll; Carsten Bøcker Pedersen; Yan Holtz; Michael E Benros; Søren Dalsgaard; Peter de Jonge; Chun Chieh Fan; Louisa Degenhardt; Andrea Ganna; Aja Neergaard Greve; Jane Gunn; Kim Moesgaard Iburg; Lars Vedel Kessing; Brian K Lee; Carmen C W Lim; Ole Mors; Merete Nordentoft; Anders Prior; Annelieke M Roest; Sukanta Saha; Andrew Schork; James G Scott; Kate M Scott; Terry Stedman; Holger J Sørensen; Thomas Werge; Harvey A Whiteford; Thomas Munk Laursen; Esben Agerbo; Ronald C Kessler; Preben Bo Mortensen; John J McGrath
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596

9.  Social criticism moderates the relationship between anxiety and depression 10 years later.

Authors:  Kayla A Lord; Nicholas C Jacobson; Michael K Suvak; Michelle G Newman
Journal:  J Affect Disord       Date:  2020-05-21       Impact factor: 4.839

10.  Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence.

Authors:  Emma E M Knowles; Samuel R Mathias; Godfrey D Pearlson; Jennifer Barrett; Josephine Mollon; Dominique Denbow; Katrina Aberzik; Molly Zatony; David C Glahn
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.